Berberine: A novel therapeutic strategy for cancer.
Parisa SamadiParisa SarvarianElham GholipourKarim Shams AsenjanLeili Aghebati-MalekiRoza MotavalliMohammad Hojjat-FarsangiMehdi YousefiPublished in: IUBMB life (2020)
Cancer, even currently, is one of the main reasons for mortality and morbidity, worldwide. In recent years, a great deal of effort has been made to find efficient therapeutic strategies for cancer, however, particularly with regards to side effects and the possibility of complete remission. Berberine (BBR) is a nature-driven phytochemical component originated from different plant groups such as Berberis vulgaris, Berberis aquifolium, and Berberis aristata. BBR is a well-known nutraceutical because of its wide range of pharmacological activities including anti-inflammatory, antidiabetic, antibacterial, antiparasitic, antidiarrheal, antihypertensive, hypolipidemic, and fungicide. In addition, it exhibits inhibitory effects on multiple types of cancers. In this review, we have elaborated on the anticancer effects of BBR through the regulation of different molecular pathways such as: inducing apoptosis, autophagy, arresting cell cycle, and inhibiting metastasis and invasion.
Keyphrases
- cell cycle
- papillary thyroid
- squamous cell
- anti inflammatory
- oxidative stress
- endoplasmic reticulum stress
- cell death
- signaling pathway
- cell proliferation
- blood pressure
- childhood cancer
- cardiovascular events
- coronary artery disease
- systemic lupus erythematosus
- lymph node metastasis
- silver nanoparticles
- cell cycle arrest
- wound healing